Design Therapeutics

DSGN

Market cap $888M

14.22 USD

+0.12

0.85%

At close Updated May 8, 4:00 PM EDT

Pre-market

After hours

14.10

-0.12

0.84%

1 day

0.85%

5 days

5.72%

1 month

12.23%

3 months

36.99%

6 months

91.39%

Year to date

56.26%

1 year

303.98%

5 years

-49.77%

10 years

-65.73%

About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Employees: 54

Healthcare Biotechnology